期刊文献+

热休克蛋白90抑制剂诱导Kasumi-1细胞凋亡和分化的机制探讨 被引量:1

The heat shock protein 90 inhibitor induces apoptosis and differentiation of Kasumi-1 and its mechanisms
原文传递
导出
摘要 目的探讨热休克蛋白90(HSP90)抑制剂17-丙烯胺-17-去甲氧格尔德霉素(17AAG)诱导白血病细胞生长抑制、分化和凋亡作用。方法应用MTT比色法观察17AAG对白血病细胞系Kasumi-1细胞的生长抑制作用,用流式细胞术分析细胞周期和分化抗原的表达,用Annexin V标记、DNA凝胶电泳和流式细胞术分析细胞凋亡,Western blot检测干细胞因子受体(KIT)蛋白水平,RT-PCR测定c-kit mRNA水平。结果17AAG明显抑制Kasumi-1细胞的生长,半数抑制浓度(IC50)为0.62μmol/L;17AAG诱导Kasumi-1细胞凋亡呈时间、剂量依赖性,17AAG处理24h早期凋亡细胞增加,48h晚期凋亡细胞增加,早期凋亡细胞减少。17AAG可诱导Kasumi-1细胞髓系分化抗原CD11b及CD15表达增加,并呈剂量和时间依赖性。经17AAG作用后细胞阻滞于G0/G1期,伴有S期细胞减少。Western blot检测发现17AAG可降低KIT水平,处理2h开始减少,处理20h后KIT基本消失,但c-kit mRNA水平并未受影响。结论HSP90抑制剂17AAG通过降解KIT蛋白抑制Kasumi-1细胞生长,使细胞阻滞于G0/G1期,诱导其发生凋亡及部分分化。 Objective To explore the effect of 17-allylamide-17-demethoxygeldanamycln(17AAG) , a heat shock protein 90 (HSP90) inhibitor , on the growth, differentiathm and apoptosis of leukemic Kasumi-1 cells. Methods Kasumi-1 cells were lreated with 17AAG at differenl concentrations in suspension culture. Cell proliferation was analysed by MTT assay, expression of myeloid-specific differentiation antigen and c.ell cycle by flow cytometr? , cell apoptosis by annexin V staining , agrose gel electrophoresis and flow eytometry. KIT protein was analysed bv Western blot and c-kit mRNA by RT-PCIL Results 17AAG treatment caused a dose-dependent inhibition of the cell proliferation with the IC50 of 0.62 μmol/L. A dose-dependent increase in early apoptosis occured at 24 hours treatment and in late apoptosis at 48 hours treatment. 17AAG induced a lime- and dose-dependent increase in expression of myeloid cell surface protein CD11b and CD15, a progressive decline in S-phase cell fraction and an increase in G0/G1 cells . When Kasumi-1 cells were incubated with 1 μmol/L of 17AAG, KIT protein began to decrease at 2 hours and KIT protein could hardly be detected at 20 hours, but c-kit mRNA was not decreased. Conclusion 17AAG treatment of Kasu- mi-1 cells eouht lower KIT protein expression, inhibil cell proliferation, induce cell partial differentiation, apoptosis and accumulation in G0/G1 phase .
机构地区 中国医学科学院
出处 《中华血液学杂志》 CAS CSCD 北大核心 2005年第12期728-731,共4页 Chinese Journal of Hematology
基金 国家自然科学基金资助项目(30370593) 天津市科技发展计划项目(05YFSZSF02400)
关键词 基因 c-kit 细胞系 Kasumi-1 细胞分化 细胞凋亡 抗生素类 抗肿瘤 Gene, c-kit Cell line, Kasumi-1 Differentiation Antibiotics, antitumor
  • 相关文献

参考文献7

  • 1Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol,1998, 42: 273-279.
  • 2Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor ( c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood,2001,97: 1413-1421.
  • 3Kamal A,Thao L,Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature,2003,425: 407-410.
  • 4Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t (8;21 ) -kit mutant model for acute myeloid leukemia. Leuk Lymphoma,2005, 46: 247-255.
  • 5Moriyama Y, Tsujimura T, Hashimoto K, et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J Biol Chem, 1996, 271:3347-3350.
  • 6Beghini A, Cairoli R, Morra E, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells, Molecules & Diseases, 1998a, 24: 262-270.
  • 7Beghini A, Magnani I, Ripamonti CB, et al. Amplification of a novel KIT activating mutation Asn822-Lys in the Kasumi-1 cell line: a t( 8;21)-kit mutant model for acute myeloid leukemia. Hematol J,2002,3:157-163.

同被引文献9

  • 1Schulte TW, Neckers LM. The benzoquinone ansamycin 17- allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol, 1998, 42 : 273- 279.
  • 2Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine klnase receptor. Cell, 1990, 63:213-224.
  • 3Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97: 1413-1421.
  • 4Ma Y, Zeng S, Metcalfe DD, et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other kit kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 2002, 99: 1741-1744.
  • 5Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia, 2001, 15: 1537-1543.
  • 6Blagosklonny MV. STI-571 must select for drugresistant cells but ‘no cell breathes fire out of its nostrils like a dragon'. Leukemia, 2002, 16 : 570-572.
  • 7Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 2002, 100: 3041-3044.
  • 8Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8; 21) -kit mutant model for acute myeloid leukemia. Leuk Lymphoma, 2005, 46: 247-255.
  • 9Banerji U, O' Donnell A, Scurr M, et al. Phase Ⅰ pharmaeokinetic and pharmacodynamic study of 17-allylamino-17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol, 2005, 23 : 4152-4161.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部